These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1448 related articles for article (PubMed ID: 17092765)
1. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Assaraf YG Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765 [TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. Hooijberg JH; de Vries NA; Kaspers GJ; Pieters R; Jansen G; Peters GJ Cancer Chemother Pharmacol; 2006 Jul; 58(1):1-12. PubMed ID: 16362298 [TBL] [Abstract][Full Text] [Related]
5. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. Ifergan I; Shafran A; Jansen G; Hooijberg JH; Scheffer GL; Assaraf YG J Biol Chem; 2004 Jun; 279(24):25527-34. PubMed ID: 15047700 [TBL] [Abstract][Full Text] [Related]
6. Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line. Rhee MS; Schneider E Biochem Pharmacol; 2005 Jan; 69(1):123-32. PubMed ID: 15588721 [TBL] [Abstract][Full Text] [Related]
7. Folylpoly-γ-glutamate synthetase: A key determinant of folate homeostasis and antifolate resistance in cancer. Raz S; Stark M; Assaraf YG Drug Resist Updat; 2016 Sep; 28():43-64. PubMed ID: 27620954 [TBL] [Abstract][Full Text] [Related]
8. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Volk EL; Schneider E Cancer Res; 2003 Sep; 63(17):5538-43. PubMed ID: 14500392 [TBL] [Abstract][Full Text] [Related]
9. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Wielinga P; Hooijberg JH; Gunnarsdottir S; Kathmann I; Reid G; Zelcer N; van der Born K; de Haas M; van der Heijden I; Kaspers G; Wijnholds J; Jansen G; Peters G; Borst P Cancer Res; 2005 May; 65(10):4425-30. PubMed ID: 15899835 [TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic confinement of breast cancer resistance protein (BCRP/ABCG2) as a novel mechanism of adaptation to short-term folate deprivation. Ifergan I; Jansen G; Assaraf YG Mol Pharmacol; 2005 Apr; 67(4):1349-59. PubMed ID: 15657365 [TBL] [Abstract][Full Text] [Related]
12. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells. Jansen G; Mauritz RM; Assaraf YG; Sprecher H; Drori S; Kathmann I; Westerhof GR; Priest DG; Bunni M; Pinedo HM; Schornagel JH; Peters GJ Adv Enzyme Regul; 1997; 37():59-76. PubMed ID: 9381986 [TBL] [Abstract][Full Text] [Related]
13. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Gonen N; Assaraf YG Drug Resist Updat; 2012 Aug; 15(4):183-210. PubMed ID: 22921318 [TBL] [Abstract][Full Text] [Related]
14. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Hooijberg JH; Broxterman HJ; Kool M; Assaraf YG; Peters GJ; Noordhuis P; Scheper RJ; Borst P; Pinedo HM; Jansen G Cancer Res; 1999 Jun; 59(11):2532-5. PubMed ID: 10363967 [TBL] [Abstract][Full Text] [Related]
15. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783 [TBL] [Abstract][Full Text] [Related]
16. Resistance to antifolates. Zhao R; Goldman ID Oncogene; 2003 Oct; 22(47):7431-57. PubMed ID: 14576850 [TBL] [Abstract][Full Text] [Related]
17. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Chen ZS; Robey RW; Belinsky MG; Shchaveleva I; Ren XQ; Sugimoto Y; Ross DD; Bates SE; Kruh GD Cancer Res; 2003 Jul; 63(14):4048-54. PubMed ID: 12874005 [TBL] [Abstract][Full Text] [Related]
18. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates. Sierra EE; Goldman ID Semin Oncol; 1999 Apr; 26(2 Suppl 6):11-23. PubMed ID: 10598550 [TBL] [Abstract][Full Text] [Related]
19. Anticancer antifolates: current status and future directions. McGuire JJ Curr Pharm Des; 2003; 9(31):2593-613. PubMed ID: 14529544 [TBL] [Abstract][Full Text] [Related]
20. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]